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virulence during clinical bacteriuria
Shannon I. Ohlemacher,1,2,3 Daryl E. Giblin,4 D. André d’Avignon,4 Ann E. Stapleton,5 Barbara W. Trautner,6,7 and Jeffrey P. Henderson1,2,3
Center for Women’s Infectious Diseases Research, 2Division of Infectious Diseases, 3Department of Internal Medicine, and 4Department of Chemistry, Washington University, St. Louis, Missouri, USA.

1

Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA. 6The Center for Innovations in Quality, Effectiveness and Safety (IQuESt),

5

Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA. 7Section of Infectious Diseases, Departments of Medicine and Surgery, Baylor College of Medicine, Houston, Texas, USA.

Escherichia coli and other Enterobacteriaceae are among the most common pathogens of the human urinary tract. Among
the genetic gains of function associated with urinary E. coli isolates is the Yersinia high pathogenicity island (HPI), which
directs the biosynthesis of yersiniabactin (Ybt), a virulence-associated metallophore. Using a metabolomics approach, we
found that E. coli and other Enterobacteriaceae expressing the Yersinia HPI also secrete escherichelin, a second metallophore
whose chemical structure matches a known synthetic inhibitor of the virulence-associated pyochelin siderophore system
in Pseudomonas aeruginosa. We detected escherichelin during clinical E. coli urinary tract infection (UTI) and experimental
human colonization with a commensal, potentially probiotic E. coli bacteriuria strain. Escherichelin production by colonizing
enterobacteria may help human hosts resist opportunistic infections by Pseudomonas and other pyochelin-expressing
bacteria. This siderophore-based mechanism of microbial antagonism may be one of many elements contributing to
the protective effects of the human microbiome. Future UTI-preventive probiotic strains may benefit by retaining the
escherichelin biosynthetic capacity of the Yersinia HPI while eliminating the Ybt biosynthetic capacity.

Introduction

Urinary tract infections (UTIs) are among the most common infectious diseases treated by physicians and are increasingly associated with antibiotic-resistant bacteria (1, 2). Although bacteriuria,
the presence of bacteria in the urine, is a key feature of UTI, it also
occurs frequently in the absence of symptoms. Bacteriuria seeded
from the intestinal microbiome may self-resolve, progress to UTI,
or persist asymptomatically, in which case antibiotic treatment
is not recommended (3). Indeed, recent studies support the existence of urinary tract microbiomes in otherwise healthy individuals (4). Multiple lines of evidence suggest that the microbiome can
prevent infections. Paradoxically, antibiotic treatment has been
observed to increase the risk of subsequent UTIs (5) and to increase
the risk of UTIs caused by atypical uropathogens such as Pseudomonas (6). Members of the family Enterobacteriaceae, particularly
E. coli, inhabit the intestinal microbiome and are most commonly
associated with asymptomatic bacteriuria and UTI. The early bacteriuric state from which UTIs can develop is poorly understood
and challenging to study, but it is known that UTI-associated
E. coli isolates frequently possess nonconserved genetic systems
related to virulence (7, 8).
Prominent among virulence-associated adaptations in uropathogenic E. coli (UPEC) isolates are siderophores, specialized
metabolites able to bind extracellular Fe(III) ions for nutritional
use in low-iron conditions (7, 9). High-affinity Fe(III) binding by
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siderophores helps bacteria resist host-mediated iron deprivation, a prototypical example of nutritional immunity (10, 11). Siderophores are widespread among medically important bacteria,
which often express chemically distinctive siderophore types. A
recent quantitative metabolomics study of E. coli isolates from
patients with UTI revealed that the resident intestinal strain in
each patient that successfully infected the urinary tract preferentially secreted the siderophores yersiniabactin (Ybt) and salmochelin (12). These results suggest that the early stages of ascending
UTI are competitive and favor isolates with specific siderophore
profiles. In this and other studies, Ybt, a siderophore encoded by
the Yersinia high pathogenicity island (HPI), was associated with
urinary tract virulence (7, 13–17).
The Yersinia HPI is a complex, 4-operon mobile genetic element
encoding proteins involved in Ybt biosynthesis, import, and transcriptional regulation. It is highly prevalent among clinical extraintestinal pathogenic E. coli isolates and is also found with varying
frequencies in other Enterobacteriaceae, including the eponymous
Yersinia pestis (18). Yersinia HPI genes are highly upregulated during
UTI, and Ybt is detectable in patients’ urine specimens (12, 14, 17).
Ybt, the recognized product of Yersinia HPI–positive bacteria to
date, has been distinguished from other E. coli siderophores by its
ability to form stable Cu(II) complexes. This broad-spectrum metal-
binding property enables Ybt to scavenge Fe(III) for nutritional use,
detoxify copper, and catalyze superoxide dismutation (14, 15, 19).
The multiple functions of Ybt illustrate the importance of diverse
metal ion interactions during microbial pathogenesis.
A hybrid nonribosomal peptide synthetase/polyketide synthase
(NRPS/PKS) pathway encoded on the Yersinia HPI directs the biosynthesis of Ybt. There is remarkable natural diversity in microbial
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NRPS/PKS systems, which are notable in infectious diseases as the
source of antibiotics such as mupirocin, tetracyclines, and macrolides, but also the source of many virulence-associated siderophores
such as pyochelin in Pseudomonas aeruginosa and mycobactin in
Mycobacterium tuberculosis (20–22). NRPS and PKS pathways are
characterized by their thiotemplating, assembly line mechanism,
whereby all substrates and intermediates are covalently attached
to phosphopantetheinylated carrier protein (CP) domains as they
proceed through the catalytic domains of large, multimodular biosynthetic enzymes. The Ybt biosynthetic substrates are chorismate,
3 molecules of cysteine, malonate from malonyl-CoA, and methyl
groups derived from S-adenosyl-methionine (SAM). During Ybt
biosynthesis, YbtS converts chorismate to salicylate (23), which is
activated and transferred onto the first NRPS, HMWP2 (irp2), by
YbtE. After condensing salicylate and 2 molecules of cysteine, the
last intermediate synthesized by HMWP2 is transferred onto the
hybrid NRPS/PKS HMWP1 (irp1), where malonate, another molecule of cysteine, and methyl groups are incorporated. At this point,
YbtU catalyzes an NADPH-dependent reduction of an HMWP1bound intermediate. Once the molecule is complete, Ybt is released
from the final CP domain of HMWP1 by a terminal thioesterase
domain (20, 24). Although Ybt biosynthesis has been elegantly
characterized in vitro, an untargeted survey of this pathway’s products in bacterial culture has not been reported.
In this study, comparative metabolomic profiling revealed
escherichelin, a newly appreciated cellular product of the Ybt biosynthetic pathway in E. coli and other urinary Enterobacteriaceae
isolates. Structural characterization identified escherichelin as
2-(2-hydroxyphenyl)-4,5-dihydro-[2,4]bisthiazolyl-4-carboxylic
acid, (abbreviated as HPTT-COOH from hydroxyphenyl-
thiazolyl-thiazolinyl-carboxylic acid), an Fe(III) chelator that was
previously synthesized and found to inhibit pyochelin-mediated
iron uptake in P. aeruginosa (25). Escherichelin purified from
E. coli lacks the siderophoric activity of Ybt, but inhibits P. aeruginosa growth in a pyochelin-dependent culture condition. Consistent with this activity, we observed that P. aeruginosa minimizes
escherichelin release compared with E. coli, despite generating
the same biosynthetic precursors to escherichelin during pyochelin biosynthesis. This bioactivity and its production during human
E. coli bacteriuria raises the possibility that escherichelin may help
human hosts avoid developing symptomatic UTIs from pyochelin-producing organisms. Escherichelin was detectable in a human
subject who was experimentally colonized with a derivative of the
bacterial interference strain E. coli 83972 that has been studied in
several human trials as a potential agent to prevent UTI (26, 27).
These findings reveal how a second metallophore product of the
Yersinia HPI biosynthetic system may participate in interspecies
competition during polymicrobial bacteriuria.

Results

Metabolomic profiling identifies multiple Yersinia HPI–associated
metabolites. To identify secreted metabolites associated with the
Yersinia HPI, we used liquid chromatography–mass spectrometry (LC-MS) to compare culture supernatants from UTI89, a
Ybt-producing model UPEC strain (28), and its isogenic mutant
UTI89ΔybtS that cannot perform the first committed step of
Ybt biosynthesis, salicylate synthesis (12, 23). As a control, the
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biosynthetic block in UTI89ΔybtS was experimentally overcome by chemical complementation with salicylate-supplemented medium. The metabolomic profiles from Ybt producers
(WT and UTI89ΔybtS plus salicylate) and the Ybt nonproducer
(UTI89ΔybtS) were compared using supervised principal component analysis–discriminant analysis (PCA-DA) (Figure 1A). Uniform separation of these 2 groups along the y axis of the PCA-DA
plot confirmed that extracellular metabolites can differentiate
Ybt-producing from nonproducing strains (Figure 1A).
To identify the specific extracellular metabolites that distinguish Ybt producers from nonproducers, we performed a loadings
plot analysis (Figure 1B). In this plot, features with the highest D1
loading scores are most strongly associated with Ybt producers
and are, therefore, candidates for follow-up analysis. Ybt in the
metal-free form (apo) and bound to Al(III) were among the molecular features with the highest loading scores, as expected (Table 1)
(29). We also observed dihydroaeruginoic acid (Dha), a known
metabolite of pyochelin-producing strains of P. aeruginosa (Table 1
and Supplemental Figure 1; supplemental material available online
with this article; https://doi.org/10.1172/JCI92464DS1) (30, 31).
Dha is the free form of an early phosphopanthetheine-bound
intermediate in both the pyochelin and Ybt biosynthetic pathways
(20, 32). Unexpectedly, the molecular feature with the highest
loading score was an ion with m/z 307, which is lower than apo-Ybt
(m/z 482) (Figure 1B and Table 1). Like Ybt, the molecular feature
at m/z 307, herein called escherichelin, was present in the WT and
salicylate-complemented UTI89ΔybtS supernatants but entirely
absent in ΔybtS supernatants. These results are consistent with the
production of a previously unappreciated secreted metabolite by
E. coli with an intact Yersinia HPI.
Clinical Enterobacteriaceae isolates coproduce escherichelin and
Ybt. To determine whether escherichelin production is specific to
UTI89 or is present in other bacteria encoding the Yersinia HPI,
we measured its production in a series of clinical urinary isolates
and model strains of the Enterobacteriaceae family (Figure 1C).
The UPEC model strains UTI89 and NU14 produced both Ybt
and escherichelin, whereas CFT073, a widely used UPEC model strain with known mutations in the Yersinia HPI, and the K12
strain MG1655 produced neither (33). Klebsiella pneumoniae and
Citrobacter diversus isolates that produced Ybt also produced
escherichelin (Figure 1C). These observations suggest that escherichelin production is pervasive among clinically significant Ybt-
producing Enterobacteriaceae family members.
Escherichelin production is associated with early Ybt biosynthetic
enzymes. The Yersinia HPI and other siderophore systems are regulated by Fur, an iron-responsive transcription factor, such that Ybt
biosynthesis is downregulated in iron-rich conditions. To determine whether escherichelin is similarly regulated, we measured
its secretion in a high-iron medium (complete M63 supplemented
with 16.2 mg/l ferric chloride) (34). The high-iron medium abolished escherichelin production, suggesting that it is regulated by
iron in a manner similar to that of Ybt (Figure 2A).
To better understand the relationship between escherichelin
secretion and Ybt biosynthetic genes (Figure 2B), we screened
a panel of Yersinia HPI gene deletion mutants for altered escherichelin production (Figure 2C). Mutants lacking the biosynthetic
genes ybtS, ybtE, irp1, or ybtU do not produce Ybt (Supplemental
jci.org   Volume 127   Number 11   November 2017
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Figure 1. Metabolomic analysis reveals escherichelin as an additional product of Ybt-producing E. coli. (A) Two-group PCA-DA of LC-MS data demonstrate
consistent variance in the secreted metabolomes of the Ybt producers, WT UTI89 and UTI89ΔybtS chemically complemented with salicylic acid (SA), and
the nonproducer UTI89ΔybtS. Each point indicates the average of 3 technical replicates. Five biological replicates were analyzed from each experimental
group. (B) The PCA-DA loadings plot, where each point is a molecular feature identified in the LC-MS analysis, reveals a molecular feature with m/z 307
(escherichelin) that best distinguishes Ybt producers from nonproducers. (C) LC-MS/MS chromatograms of escherichelin (left) and apo-Ybt (right) from
culture supernatants of Enterobacteriaceae isolates grown in iron-restricted medium. All of the strains that produced Ybt also produced escherichelin.

Figure 2) (23, 35–38). A mutant lacking the Yersinia HPI transcripEscherichelin is HPTT-COOH. Multiple structural analyses were
tional regulator ybtA also produces no Ybt (38, 39). Deletion of
used to determine the chemical structure of escherichelin. These
ybtT, a putative editing enzyme, exhibits an intermediate pheanalyses were guided in part by previous in vitro investigations of
notype with reduced Ybt levels (Supplemental Figure 2) (37, 38,
Ybt biosynthesis that noted a product with a positive-ion m/z of
40). These isogenic mutants are not attenuated for growth in
307 that was identified as 2-(2-hydroxyphenyl)-4,5-dihydro-[2,4]
iron-restricted medium (38). Among Ybt-null strains, extracellubisthiazolyl-4-carboxylic acid (abbreviated as HPTT-COOH from
lar escherichelin was undetectable in the culture supernatants of
hydroxylphenyl-thiazolyl-thiazolinyl-carboxylic acid) (24, 41–44).
UTI89ΔybtS, ΔybtE, and ΔybtA (the 2 early biosynthetic genes and
HPTT-COOH is a truncated version of Ybt that arises when a
transcriptional regulator, respectively). In contrast, escherichelin
biosynthetic intermediate (Figure 2B, top structure) derived from
was detectable in supernatants from UTI89Δirp1 and ΔybtU, the
salicylate and 2 cysteines is released from the first NRPS protein,
late Ybt biosynthetic pathway deletion mutants (Figure 2C). IntraHMWP2 (irp2), and spontaneously oxidized. High-resolution MS
cellular escherichelin levels followed a trend nearly identical to
of escherichelin yielded an exact mass of 307.0216 for the [M+H]+
that of the extracellular levels between strains (Supplemental Figion, supporting an empiric formula of C13H10N2O3S2 (calculated
ure 3). Overall, these patterns favor biosynthesis, rather than celmass: 307.0206 for C13H11N2O3S2+). To determine whether eschelular export, as the major determinant of escherichelin secretion.
richelin is synthesized from salicylate, we chemically complementThe requirement of early Ybt biosynthetic genes for eschericheed UTI89ΔybtS with 13C6-salicylate and analyzed the supernatant
lin production is consistent with it being a Yersinia HPI product.
by LC-MS. Upon 13C6-salicylate complementation, escherichelin
The observation that late biosynthetic mutants (UTI89Δirp1 and
at m/z 307 disappeared, and a new molecular feature at m/z 313
ΔybtU) produce escherichelin, but not Ybt,
further suggests that escherichelin is a de
novo metabolite and not a Ybt breakdown Table 1. Molecular features with the highest loading scores are candidate small molecules
product. The diminished, but not absent, associated with Ybt biosynthesis
escherichelin levels in late biosynthesis
Loading scoreA
m/z
Retention time (min)
Identification
Ref.
mutants (UTI89Δirp1 and ΔybtU, Figure Rank
1
0.393
307.0
15.8
escherichelin
2C) mirror the diminished irp2 expression
0.234
224.1
12.8
Dha
30–32
observed with analogous Y. pestis mutants 2
14
3
0.203
295.0
17.1
apo-Ybt peak 2B
(36, 37). Although the precise reason for
4
0.193
188.1
4.9
this altered gene expression in the mutants
5
0.187
498.1
10.8
remains unclear, it has been proposed that
6
0.169
482.1
17.1
apo-Ybt peak 2
14, 19
feedback regulation from a late biosyn7
0.152
313.0
7.3
thetic gene product is reduced, leading to 8
0.143
506.1
11.6
Al(III)-Ybt
29
the downregulation. The feedback regu- 9
0.137
482.1
16.3
apo-Ybt peak 1
14, 19
lation is believed to be mediated by YbtA, 10
14
0.129
295.1
16.4
apo-Ybt peak 1B
a member of the AraC transcription factor A
The loading scores come from the loading plot of the positive-ion LC-MS data (Figure 1B).
family whose members typically respond to BSource-decay fragment of apo-Ybt.
allosteric activation by metabolites.
4020
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Figure 2. Escherichelin production is iron repressible and dependent on early Ybt biosynthetic enzymes. Escherichelin levels in culture supernatants
were quantified by LC-MS/MS relative to a 13C-IS. (A) UTI89 grown in complete M63 medium with or without 16.2 mg/l FeCl3 (34). Data represent the mean
of 3 replicates, with SD plotted. ***P < 0.001, by unpaired t test. (B) Schematic of the Ybt biosynthetic pathway. Black zig-zag line designates a phosphopantetheine group covalently attached to the biosynthetic enzyme. Green designates chemical moieties built by early biosynthetic enzymes (YbtS, YbtE,
and HMWP2), and blue designates chemical moieties built by late biosynthetic enzymes (HMWP1 and YbtU). (C) Isogenic mutants of UTI89 in select genes
of the Yersinia HPI grown in iron-restricted medium. Data represent the mean of 8 replicates, with SD plotted.

appeared at the same retention time, consistent with incorporation
of the six 13C atoms (Figure 3, A and B). The empiric formula and
heavy isotope labeling are consistent with a biosynthetic product
derived from salicylate and 2 cysteines.
Information about the connectivity of escherichelin’s atoms
was obtained using tandem MS (MS/MS) and 1H-NMR. MS/
MS of the escherichelin [M+H]+ ion yielded unique fragments
arising from neutral losses of 46, 78, and 104 Da (Figure 3C).
The 46-Da neutral loss is consistent with an equivalent loss of
HCOOH (formic acid or sequential loss of H2O and CO) and
supports the presence of a carboxylic acid. The atypical neutral losses of 78 and 104 Da are consistent with equivalent
cleavages through the thiazoline ring to lose neutral fragments
containing the carboxylic acid and either nitrogen [M-78]+ or
sulfur [M-104]+ (Figure 3A). To further investigate the structure, we performed one-dimensional 1H and two-dimensional
1
H correlation spectroscopy (COSY) NMR experiments. The
chemical shifts and assignments were as follows: 1H NMR (500
MHz, CDCl3, δ), 8.15 (s, 1H,-CH=); 6.97, 7.1, 7.4, and 7.63 (s, 1H,
aromatic), 5.05 (m, ~1H, CH-COOH), and 3.2 (dd, 2H, -CH2).
The 5.05 multiplet was partially obscured by a solvent impurity,
preventing an accurate signal assignment. The chemical shifts
at 6.97, 7.1, 7.4, and 7.63 ppm that each integrate to 1 proton and
correspond to aromatic protons further support the presence of
a salicylate-derived aromatic ring. A singlet at 8.15 ppm is consistent with the vinylic proton of the thiazole, and coupled resonances at 3.2 and 5.05 ppm are consistent with the presence of
the methylene protons and the C-H proton of the thiazoline ring,

respectively (Supplemental Figure 4). Together, the molecular
formula from high-resolution MS, the MS/MS fingerprint, and
the 1H-NMR chemical shifts support HPTT-COOH as the escherichelin structure. Escherichelin corresponds to an oxidized
form of a Ybt biosynthetic intermediate and is structurally similar to the P. aeruginosa siderophore pyochelin. Escherichelin and
pyochelin differ in the oxidation state of their first heterocyclic
ring, and pyochelin is also further modified by the reduction of
the second thiazoline to a thiazole and by N-methylation (45).
Escherichelin binds Fe(III). Given that escherichelin is produced
by a siderophore biosynthetic pathway, regulated by Fur, and retains
some of the functional groups required for metal binding by Ybt and
pyochelin, we assessed the ability of purified escherichelin to form
an Fe(III) complex in aqueous solution with UV-visible spectroscopy. As reported in previous studies, Fe(III) addition caused notable
shifts in the UV-visible absorption spectra of Ybt and pyochelin,
consistent with the formation of Fe(III) complexes (19, 46, 47). The
escherichelin UV-visible absorption spectrum was similarly shifted
following exposure to equimolar Fe(III) (Figure 3D). Cu(II) addition
caused a qualitatively distinct shift from Fe(III) (Figure 3D). These
results demonstrate that escherichelin, like Ybt and pyochelin, is a
bacterial metallophore that forms Fe(III) and Cu(II) complexes.
To determine whether escherichelin binds metal ions in a manner similar to Ybt and pyochelin, we conducted quantum-based
calculations using density functional theory (DFT). These calculations predict stable 1:1 and 1:2 complexes of Fe(III)-escherichelin in a hexacoordinate octahedral geometry (Figure 3, E and F).
In the 1:1 complex, Fe(III) is bound by the salicylate oxygen, the 2
jci.org   Volume 127   Number 11   November 2017
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Figure 3. Identification of escherichelin as HPTT-COOH, a metallophore inhibitor of Pseudomonas iron uptake. (A) Multiple chemical characterizations
identify escherichelin as HPTT-COOH, a compound shown to inhibit pyochelin-mediated iron uptake in Pseudomonas. The positions of 13C salicylate incorporation are indicated in green, while MS/MS neutral losses are indicated as dashed lines. (B) Mass spectra at the retention time for escherichelin from WT
UTI89, UTI89ΔybtS, and 13C6-SA–supplemented UTI89ΔybtS culture supernatants revealed that 6 carbons in escherichelin are derived from salicylate. (C) MS/
MS product ion spectrum of escherichelin. The 46-Da neutral loss indicates the presence of a carboxylic acid group, and the 87- and 104-Da losses correspond
to fragmentation within the thiazoline ring. (D) UV-visible absorption spectra of purified escherichelin incubated with equimolar FeCl3 or CuSO4. (E and F) DFT
simulations of escherichelin bound to Fe(III) in a 1:1 (E) and 2:1 (F) complex. The simulations predict stable Fe(III)-escherichelin complexes with hexacoordinate octahedral geometry. (G) UTI89 growth curve in the presence or absence of a ferric ion chelator (0.5 mM EDDHA) and/or ferric ion supplementation (1 μM
FeCl3). Growth was monitored by OD at 600 nm (OD600). Data represent the mean of 3, with SD plotted. (H) PW5011 (pvdA-E02::ISlacZ/hah), a P. aeruginosa
strain MPAO1 transposon mutant (55, 56) expressing pyochelin as its sole siderophore, was grown in succinate medium for 20 hours in the presence of increasing escherichelin concentrations relative to vehicle control. Bacterial growth was quantified by enumerating CFU/ml and is expressed as a percentage of the
vehicle control. Data represent the mean of 3, with the SEM plotted. *P < 0.01 and **P < 0.001, by 1-way ANOVA with Dunnett’s multiple comparisons test.

heterocyclic nitrogens, and the carboxylic acid group in the equatorial positions and by 2 water molecules in the axial positions.
In the 1:2 complex, the carboxylic acids of the 2 escherichelin
molecules and water do not participate as ligands. Instead, the
nitrogen atoms and phenolic oxygen atoms of 2 the escherichelins occupy all of the liganding positions. Pyochelin binds Fe(III)
in similar 1:1 and 1:2 complexes with the same ligands (48, 49). As
with Ybt, escherichelin is also predicted to form a stable Cu(II)
complex (Supplemental Figure 5). Overall, the calculated metal
4022
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ion coordination in the Fe(III)- and Cu(II)-escherichelin complexes is similar to that observed for metal-Ybt complexes and
Fe(III)-Pch (15, 19, 48, 50). These results support the idea that
escherichelin is an Fe(III)-binding molecule.
Escherichelin does not support iron-dependent E. coli growth.
To determine whether escherichelin, like Ybt, can promote iron-
dependent growth in E. coli possessing Yersinia HPI-encoded transport genes, we measured UTI89 growth in a previously described
siderophore-dependent growth assay (Figure 3G) (16, 19). Addition
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Figure 4. Escherichelin release is suppressed in P. aeruginosa relative to E. coli. LC-MS/MS chromatograms of extracellular metabolites released from Ybt
and pyochelin biosynthetic enzymes in the E. coli strain UTI89 (left) and the P. aeruginosa strain PA01 (right) cultured in iron-deficient media are displayed
in the center. Chromatograms are identically scaled, except for P. aeruginosa pyochelin, which is at ×0.1 magnification. The accompanying illustrations
depict the sequential release of Dha, escherichelin, pyochelin, and apo-Ybt from multidomain NRPS/PKS enzymes associated with early (green rectangles)
and late (blue rectangles) biosynthesis of Ybt (left) and pyochelin (right). Thick black arrows designate the biosynthetic steps at which metabolite intermediates transfer from early to late proteins.

of the iron chelator EDDHA to the test medium causes substantial
growth restriction. As previously observed, addition of Ybt that
has been preincubated with equimolar Fe(III) restores growth to a
density comparable to that of the unchelated medium. In contrast,
addition of escherichelin that has been preincubated with equimolar
Fe(III) resulted in no significant growth enhancement (Figure 3G).
Although both escherichelin and Ybt bind Fe(III), these results show
a nonequivalent ability to support iron-limited growth. This discrepancy may arise from differences in Fe(III) affinity or from differential recognition of the complexes by bacterial transport proteins.
P. aeruginosa growth inhibition by escherichelin. The deficient
siderophoric activity of escherichelin raises the possibility that
this molecule performs an alternative function. In prior work by
Mislin et al., escherichelin (previously designated HPTT-COOH)
was synthesized as a pyochelin analog (51) and found to act as a
competitive inhibitor of pyochelin-mediated iron import through
the TonB-dependent outer membrane transporter FptA in P. aeruginosa (25, 51, 52). Escherichelin did not mediate iron uptake and
inhibited Fe(III)-pyochelin transport through FptA with a Ki of 27
nM. In silico docking simulations could rationalize these results
through occupancy of the Fe(III)-pyochelin binding site of FptA
by a 1:2 Fe(III)-escherichelin complex [Fe(III):escherichelin] (25,
48). Given that escherichelin can bind Fe(III) in solution but does
not possess canonical siderophoric activity, we hypothesized that
it may be produced by UPEC to inhibit pyochelin uptake by competing P. aeruginosa strains in the urinary tract.

To determine whether escherichelin can inhibit ferric pyochelin uptake, we examined the effect of escherichelin on growth
of the P. aeruginosa strain PAO1. Although pyochelin enhances
P. aeruginosa growth during infections (53, 54), it is functionally
redundant with pyoverdin, a second siderophore, during in vitro
growth in standard culture media. Escherichelin addition to a
defined, iron-restricted minimal medium caused a dose-dependent reduction in growth of a pyoverdin-deficient P. aeruginosa
mutant strain, PW5011 (Figure 3H) (55–57). These results are consistent with the escherichelin-mediated inhibition of iron uptake
in P. aeruginosa noted by Mislin et al. (25).
P. aeruginosa minimizes escherichelin production. Production of
a P. aeruginosa iron uptake inhibitor from the enzyme-bound precursor hydroxyphenyl-thiazolinyl-thiazolinyl-S-ppant (Figure 2B,
top structure) presents a potential paradox, because this enzymebound species is also a biosynthetic intermediate of pyochelin
(20). Escherichelin release from this intermediate in P. aeruginosa
would be expected to autoantagonize pyochelin-mediated iron
uptake. To determine whether P. aeruginosa minimizes escherichelin release relative to E. coli, we compared escherichelin production between UTI89 and PAO1 in low-iron medium. Despite
comparable growth of both strains and substantial pyochelin
production by PAO1, extracellular and intracellular levels of escherichelin were markedly lower in PAO1 than in UTI89 (Figure 4
and Supplemental Figures 6 and 7). This may reflect selective pressure on the P. aeruginosa pyochelin biosynthetic pathway to avoid
jci.org   Volume 127   Number 11   November 2017
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Escherichelin is produced during experimental
bladder colonization with an E. coli 83972 strain. The
concept that one bacterial strain or species can prevent infection by another — termed bacterial interference — has been of longstanding interest in infectious diseases (61–63). In this context, an avirulent
strain or species that outcompetes more pathogenic
strains may be useful as a probiotic to prevent infections. E. coli 83972, which asymptomatically colonized a young Swedish girl for over 2 years (64), has
been used in multiple UTI prevention studies (26,
27, 63, 65–70). Among these studies are anecdotal
reports of protection against symptomatic P. aeruginosa UTIs, including 1 patient with asymptomatic
cocolonization of 83972 and P. aeruginosa that progressed to UTI following loss of 83972 (26, 66).
E. coli 83972 possesses the Yersinia HPI (71, 72)
and was observed to produce escherichelin in iron-
restricted medium (data not shown).
To determine whether 83972 secretes escheFigure 5. Escherichelin is produced during clinical E. coli UTI and experimental human
richelin
in the human urinary tract, we analyzed urine
colonization with the asymptomatic bacteriuria strain E. coli HU2117. (A) Representative
specimens
following experimental colonization of
LC-MS/MS chromatogram for escherichelin in urine from a patient with an uncomplicated
catheter-dependent patients with an 83972-derived
UTI caused by a Ybt-producing UPEC strain (results from 18 urine samples are shown in
Table 1). Escherichelin coeluted with the 13C-IS (green). Escherichelin was undetectable
E. coli strain lacking the virulence-associated papG
in urine from a patient with a UTI caused by a Ybt-nonproducing UPEC strain. (B and C)
adhesin (E. coli HU2117) (27). Bladder colonization
LC-MS/MS chromatograms for escherichelin in urine from subjects who were successfully
was established by inserting urinary catheters that
(B) or unsuccessfully (C) colonized with E. coli HU2117. The days after insertion of the
had been precoated with E. coli HU2117. LongitudiHU2117-coated study catheter are indicated on the left. Where microbiological culture data
nal urine specimens were available from 1 subject
were available, the results are listed to the right of the chromatograms. The colonized subject (B, subject 9) was colonized with HU2117 for 57 days and then developed a febrile UTI
(104 days for subject 9) who became colonized with
caused by another strain of E. coli on day 76, after colonization had ended. On day 7,
HU2117 and another subject who was unsuccessfulP. aeruginosa was also present in this subject’s urine. Escherichelin was detectable
ly colonized (51 days for subject 10). Both subjects
throughout the colonization period and during the symptomatic E. coli UTI. The noncoloshowed evidence of polymicrobial urinary tract colnized subject (C) did not show a presence of HU2117 after day 0, when the study catheter
onization during the collection periods. In subject 9,
was inserted, and escherichelin was not detected in the longitudinal samples. P. vulgaris,
Proteus vulgaris; A. faecalis, Alcaligenes faecalis; O. anthropi, Ochrobactrum anthropi;
escherichelin was detected throughout the 57 days
B. bronchiseptica, Bordetella bronchiseptica; S. epidermis, Staphylococcus epidermidis.
of documented HU2117 colonization, reaching a
maximum on day 7 after catheterization (Figure 5B).
P. aeruginosa was detected by culture in the urine on
day 7 but was unassociated with symptoms and became undetectinhibiting pyochelin-mediated iron uptake, as well as an opposing
able in subsequent specimens (27). On day 76, HU2117 colonizaselective pressure on E. coli to suppress competing Pseudomonas
tion had ended, and the subject developed a febrile UTI caused by
strains in polymicrobial settings.
another E. coli strain, which was accompanied by detectable eschEscherichelin is produced during human E. coli cystitis. Enteroerichelin. Subject 10 was not colonized with HU2117 or any other
bacterial bacteriuria may be a frequent occurrence in the human
E. coli strains after day 0, and escherichelin was undetectable in
urinary tract and is frequently accompanied by other flora (58–60).
all specimens (Figure 5C). These results are consistent with escheWhen native enterobacteria in the microbiome are suppressed or
richelin production by HU2117 in conditions in which P. aeruginosa
eliminated by antibiotic treatment, P. aeruginosa UTIs become
is encountered, which may contribute to the ability of this strain to
more frequent (6). Therefore, we hypothesize that escherichelin
suppress symptomatic P. aeruginosa UTI.
release during enterobacterial bacteriuria prevents P. aeruginosa
UTI. To determine whether Enterobacteriaceae produce escherichelin in the human urinary tract, we used LC-MS/MS to detect
Discussion
escherichelin in urine from 18 patients with uncomplicated cystitis
In this study, we used isogenic mutants in the Yersinia HPI and
caused by Ybt-producing E. coli. Escherichelin was detectable in
untargeted LC-MS–based metabolomics to identify a previously
8 of the 18 samples (Figure 5A and Table 2). In four escherichelinunappreciated biosynthetic product of bacteria carrying the Yersinia
positive specimens, Ybt was undetectable. As expected, eschHPI. Escherichelin had previously been observed during the in
erichelin was undetectable in patients with cystitis caused by
vitro reconstitution of Ybt biosynthesis (24), but we now identify it
Gram-positive species (Staphylococcus saprophyticus or Enterococas a physiologically relevant product of the Ybt biosynthetic pathcus sp.) or Ybt-null E. coli. These results demonstrate that E. coli
way. The name escherichelin was chosen to recognize its identifican produce escherichelin in the human bladder.
cation as a natural product from pathogenic E. coli (escheri-) and its
4024
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Table 2. Escherichelin and Ybt prevalence in urine samples
from patients with uncomplicated UTI
Patient
no.
3
5
2
4
8
12
14
15
17
24
33
39
41
43
51
54
56
66
74
80
83
95

Causative
species
S. saprophyticus
Enterococcus spp.
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli
E. coli

Ybt-producing Escherichelin in
in culture
urine sample
–
–
+
+
+
–
+
+
+
–
+
+
+
+
+
ND
+
+
+
+
+
+

–
–
–
–
–
–
–
+
–
–
–
–
–
–
+
+
+
+
+
+
–
+

Ybt in
urine sample
–
–
–
–
–
–
–
+
–
–
–
–
–
–
–
+
–
–
–
+
–
+

ND, strain did not grow in complete M63, so Ybt production in culture could
not be determined.

metal chelating properties (-chelin). Escherichelin may have eluded discovery in the 20 years since the identification of Ybt because
its reverse-phase chromatographic and UV-visible spectroscopic
characteristics are nearly identical to those of Ybt, making them
difficult to resolve. Although escherichelin lacks the siderophoric
activity of Ybt, the fortuitous synthesis of escherichelin prior to the
present discovery (51) and the demonstration of its ability to inhibit
pyochelin-mediated iron uptake by P. aeruginosa (25) suggests an
alternative functional rationale for escherichelin’s secretion by
Enterobacteriaceae: to inhibit iron uptake in a competing species.
This niche exclusion function is consistent with clinical observations regarding Pseudomonas UTI, asymptomatic bacteriuria, and
protective influences of a healthy human microbiome.
Other microbes have demonstrated an ability to interfere
with pyochelin function. Pseudomonas fluorescens can synthesize
an enantiomeric form of pyochelin (enantio-pyochelin), which
preserves the coordinating properties of pyochelin while resisting FptA-mediated uptake by pyochelin-producing competitor strains. The fungal commensal and opportunistic pathogen
C. albicans suppresses pyochelin biosynthesis, interfering with
P. aeruginosa virulence, but not colonization, in a murine model
(73). A detailed study by Mislin et al. (25) revealed that escherichelin acts as a drug-like inhibitor of pyochelin-mediated iron uptake.
Specifically, escherichelin competitively inhibited radioactive 55Fe
iron uptake through the pyochelin outer membrane transporter
FptA, with a Ki of 27 nM. A molecular docking simulation sup-

ports an inhibitory mechanism based on occupancy of the pyochelin-binding site with a 1:2 Fe(III)-escherichelin complex. Here,
we experimentally confirmed that escherichelin forms an Fe(III)
complex and found by quantum calculations that this complex
favors the molecular geometry used in the docking model of Mislin et al. (25). We also experimentally confirmed that escherichelin
purified from E. coli inhibits P. aeruginosa pyochelin–dependent
growth. Overall, the results are consistent with a noncanonical siderophore function for escherichelin as an effector of interspecies
bacterial antagonism. To our knowledge, this is the first report of a
microbial natural product that is a direct inhibitor of a competing
species’ siderophore transport system.
Multiple studies have implicated the pyochelin siderophore
system in virulence (74–76), including genetic abrogation of pyochelin-mediated iron uptake that diminished P. aeruginosa virulence in murine infection models (53, 54). In this context, escherichelin-producing Enterobacteriaceae at colonized devices or
mucosal surfaces may prevent P. aeruginosa from progressing to
symptomatic infection by chemically inhibiting pyochelin-mediated iron uptake. This scenario may occur at epithelial surfaces
during transient or persistent colonization of the urinary tract. The
apparent ability of asymptomatic bacteriuria E. coli strain 83972
(or its derivative HU2117) to produce escherichelin during experimental human colonization is consistent with a model in which
E. coli in the urinary tract secretes an antivirulence compound
against P. aeruginosa (26, 27). Expression of the virulence-associated Yersinia HPI in colonizing Enterobacteriaceae such as E. coli
strain 83972 may thus confer both risk (from Ybt production) and
benefit (escherichelin production) to patients (77). Engineering an
E. coli strain that colonizes the bladder and retains escherichelin,
but not Ybt, production may be a desirable bacterial interference
strategy in the future. Lack of a recognized asymptomatic bacteriuria mouse model and mouse-specific bacterial tissue tropisms in
the urinary tract suggest that these future engineered strains may
be best evaluated in human studies.
Whereas the Ybt and pyochelin biosynthetic machineries
both generate the immediate enzyme-bound precursor to escherichelin (Figure 2B, top structure), the pyochelin machinery in
P. aeruginosa releases less escherichelin than does the Ybt machinery in E. coli. This is consistent with the evolutionary hypothesis
that the pyochelin biosynthetic pathway evolved to avoid auto
inhibition of Fe(III)-pyochelin uptake. The architectures of these
pathways provide a potential explanation for this difference in
escherichelin production. Specifically, the escherichelin precursor
in the Ybt pathway forms at the terminus of the first NRPS protein (HMWP2), where it must be transferred in trans to the second
NRPS/PKS protein (HMWP1). In the pyochelin pathway, this same
intermediate is instead passed in cis to a subsequent domain on the
same protein (PchF). In the Ybt biosynthetic pathway, this handoff
between proteins appears to be particularly susceptible to spontaneous hydrolysis, thereby allowing it to become a branch point
in which the intermediate can proceed to form either escherichelin or Ybt. In contrast, this immediate precursor to escherichelin
may be less vulnerable to hydrolysis off the pyochelin biosynthetic
machinery, because it does not occur at a handoff between proteins. During pyochelin biosynthesis, Dha is passed in trans from
PchE to PchF, and it is Dha, rather than escherichelin, that accujci.org   Volume 127   Number 11   November 2017
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mulates in P. aeruginosa. Intriguingly, Dha has been shown to
possess antimicrobial activity against fungal and bacterial species
(31). Applied generally, this suggests that the NRPS/PKS pathways may evolve to segregate modules onto separate proteins at
steps in the pathway where a “leak” yields a product that benefits
the organism. Whether the branch point in Ybt biosynthesis that
yields escherichelin and the similar branch points in other NRPS/
PKS pathways reflect uncontrolled “leaks” or regulated processes is unclear. Further biochemical and genetic characterization of
these pathways may address this possibility.
Advances in MS and the application of powerful computational
and statistical analyses to the data have led to the fruitful application of metabolomics to secondary metabolism (78). MS-based
metabolomics is enabling the rapid discovery of secondary metabolites from newly sequenced bacterial strains as well as novel
products from well-studied pathways (79). This approach moves
beyond the functional screens that were historically used to discover siderophores and other natural products. With this unbiased approach, one is open to discovering any molecule that is
chemically compatible with the instrumentation, regardless of the
molecule’s function. Continued application of LC-MS–based
metabolomics to other siderophore biosynthetic pathways will
further our understanding of iron acquisition by pathogens.

Methods

Bacterial strains and culture conditions. The well-characterized, cystitis-derived model UPEC strain UTI89 was used for these studies (28).
The creation of the isogenic mutants in ybtS, ybtE, irp1, ybtU, ybtT,
and ybtA was previously described (12, 38). UTI89 Δirp1/entB::kan
was generated in the same manner, using the lambda red recombinase
method (80, 81). For growth under iron-restricted conditions, strains
were first grown in Luria-Bertani (LB) broth (BD Biosciences) overnight at 37 °C under shaking conditions. They were then back-diluted
1:1,000 into M63 minimal medium supplemented with 10 mg/ml niacin and 0.2% (v/v) glycerol (Sigma-Aldrich; complete M63). For salicylate complementation experiments, 50 μM salicylate or 13C6-salicylate
(Sigma-Aldrich) was also added. To achieve iron-replete conditions,
16.2 mg/l FeCl3 (Sigma-Aldrich) was added to the complete M63.
For comparison of E. coli and P. aeruginosa metabolites, the model
P. aeruginosa strain PAO1 was used (82). In these experiments, UTI89
and PAO1 were grown in complete M63 supplemented with 1% (w/v)
casamino acids (BD Biosciences). For E. coli siderophore–dependent
growth assays, the iron-limited and nutrient-rich yeast extract–casamino acids (YESCA) medium was used (1% casamino acids and 0.12%
yeast extract; BD Biosciences). All cultures were grown at 37°C under
shaking conditions for approximately 18 hours. Other model E. coli
strains (MG1655 [ref. 83], CFT073 [ref. 84], NU14 [ref. 85], and 83972
[ref. 64]) as well as clinical isolates of UPEC, K. pneumoniae, and
C. diversus were grown in the same manner.
Metabolomic analysis. For metabolomics experiments, 5 biological
replicate cultures were cultivated from 5 distinct single colonies under
iron-restricted conditions, as described above. Cultures were centrifuged at 7,142 g for 10 minutes to pellet the cells. The spent supernatants were collected and filtered through 0.22-μM filters (EMD
Millipore). A quality control sample was generated by combining an
equal volume of each sample. The samples were analyzed in technical triplicates and in a randomized order on a Shimadzu Prominence
4026
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UFLC-coupled AB Sciex 4000 QTrap mass spectrometer with a Turbo V electrospray ionization (ESI) source. The LC separation was performed on an Ascentis Express phenyl-hexyl column (100 × 2.1 mm,
2.7 μM; Sigma-Aldrich) with a 32-minute linear gradient from 2% A
(HPLC-grade water plus 0.1% [v/v] formic acid; Sigma-Aldrich) to
98% B (90% acetonitrile plus 0.1% [v/v] formic acid; EMD Millipore)
at 0.35 ml/min. The MS was operated in positive ion–enhanced MS
mode, scanning from 50 to 1,200 m/z. The quality control sample was
injected first to precondition the column and every 10 samples thereafter to assess instrument stability.
MarkerView, version 1.2.0 (Sciex) was used for the generation of
an aligned peak list and statistical analysis. The triplicate runs were
averaged, and the data were Pareto scaled for supervised PCA-DA
with 2 groups: (a) UTI89 and ΔybtS plus salicylate; and (b) ΔybtS.
Candidate molecular features were identified on the PCA-DA loading
plots and then verified by visual inspection of the LC-MS data.
Metabolite detection and quantification in bacterial culture. Escherichelin, Dha, pyochelin, and Ybt were detected in culture supernatants and cellular extracts from UTI89, PAO1, and clinical Enterobacteriaceae strains by a multiple reaction monitoring (MRM)
method on the Shimadzu Prominence UFLC-coupled AB Sciex QTrap
4000 with MS/MS transitions for escherichelin (307.0/219.9), Dha
(224.0/178.0), pyochelin (325.0/190.0), apo-Ybt (482.2/295.1), and
Fe-Ybt (535.6/349.5) and a collision energy of 37 V. The above column,
mobile phases, and flow rate were used with the following LC gradient: solvent B was held constant at 5% for 2 minutes, increased to 56%
over 8 minutes, and then increased to 98% over 2 minutes, all with a
flow rate of 0.4 ml/min.
Stable isotope dilution was used to quantify escherichelin levels.
A 13C6-escherichelin internal standard (IS) was generated by culturing
UTI89 ΔybtS in complete M63 minimal medium supplemented with
50 μM 13C6-salicylate. For quantification of extracellular escherichelin, strains were grown under iron-restricted conditions, as described
above, and 1 ml of culture supernatant was spiked with 25 μl 13C6-escherichelin IS and 6 μl FeCl3. The samples were incubated at room temperature for 10 minutes, centrifuged at 15,996 g for 3 minutes, and
extracted on C18 solid-phase extraction 96-well plates (United Chemical Technologies) with 80% methanol (Sigma-Aldrich). Samples were
then analyzed by the escherichelin-specific MRM, and escherichelin
levels were assessed by taking the peak area ratio of the native isotope
escherichelin to the IS 13C6-escherichelin. Viable CFU were measured
to ensure that all strains grew to an equal final density.
Intracellular escherichelin was extracted from 50-ml cultures grown
under iron-restricted conditions, as described above. The cultures were
centrifuged at 7,412 g for 10 minutes to pellet the cells. The supernatant
was discarded, and the cells were washed 3 times with 25 ml PBS (Sigma-
Aldrich). The pellets were then resuspended in 1.2 ml ice-cold 80% methanol, briefly vortexed, and incubated on dry ice for 30 minutes. After
thawing, the samples were centrifuged at 15,996 g for 10 minutes to pellet
the cell debris. The supernatant was retained, and 800 μl acetonitrile was
added. The mixture was incubated on ice for 15 minutes and then centrifuged at 15,996 g for 2 minutes to remove any remaining debris. 13C6-escherichelin (10 μl) IS was added to 250 μl of each sample, and escherichelin
levels were quantified by LC-MRM, as described above.
MS for escherichelin identification. A Shimadzu UFLC-coupled Agilent 6550 Q-TOF mass spectrometer with a Dual AJS ESI ion source
was used to determine the accurate mass, and therefore molecular for-
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mula, of escherichelin in UTI89 supernatant that had been prepared as
described above. LC separation was performed on an Ascentis Express
phenyl-hexyl column (100 × 2.1 mm, 2.7 μM) with the same mobile
phases as described above. The gradient was as follows: solvent B was
held constant at 2% for 1 minute, then increased to 50% over 6 minutes, then increased to 98% over 2 minutes, and then held constant
at 98% for 1 minute, all with a flow rate of 0.6 ml/min. The MS was
operated in positive-ion mode, scanning a mass range from 75 to 1,100
Da. The calculated mass for HPTT-COOH is [M+H]+ (C13H11N2O3S2+) =
307.0206, and 307.0216 was found.
MS/MS was performed on the Shimadzu Prominence UFLC-coupled AB Sciex QTrap 4000. Supernatant from UTI89 grown under
iron-restricted conditions was prepared as described above for
detection and quantification. Data were collected in the positive-ion,
enhanced product ion (EPI) mode, with the parent ion m/z set at 307
and the collision energy set at 37 V.
Escherichelin purification. Escherichelin was purified from
UTI89Δirp1/entB::kan grown under iron-restricted conditions, as
described above, with the addition of 20 μM 2,2′-dipyridiyl (Sigma-
Aldrich) and 0.1% casamino acids (w/v) to the complete M63. Culture
supernatant was applied to a methanol-conditioned C18 silica column
(Sigma-Aldrich). The column was washed with water and then eluted with 80% methanol. The eluate was dried down with a lyophilizer
(Labconco), resuspended in 20% methanol, and further purified on
a Bio-Rad BioLogic DuoFlow 10 system equipped with a QuadTec
UV-Vis detector and a Kromasil Eternity-5-phenylhexyl column (AkzoNobel). The column was run at 0.7 ml/min with water plus 0.1% formic acid (solvent A) and acetonitrile plus 0.1% formic acid (solvent B)
and the following gradient: solvent B held steady at 0% for 2.5 ml, then
increased to 30% over 2 ml, then increased to 70% over 20 ml, and
finally increased to 100% over 2 ml. Fractions containing escherichelin
were identified via UV-Vis detection at 318 nm, pooled together, and
dried down by lyophilization. Purification was confirmed by LC-MS.
NMR. Purified escherichelin was resuspended in CDCl3. One-
dimensional 1H and two-dimensional 1H COSY spectra were collected
at 20°C on a Varian Unity Inova-500 MHz instrument.
UV-Vis spectroscopy. Purified escherichelin was reconstituted to
1 mM in 50% ethanol (Sigma-Aldrich). For experiments to monitor
metal binding, escherichelin was diluted to 100 μM in water and
combined with an equimolar amount of FeCl3 or CuSO4 (Sigma-
Aldrich). The samples were incubated at room temperature for 2
hours, and then a wavelength scan was collected from 200 to 800
nm on a UV-Vis spectrophotometer (Beckman Coulter; DU800). For
each escherichelin-plus-metal scan, the instrument was blanked with
a metal-only control. For escherichelin alone, the instrument was
blanked with 5% ethanol.
E. coli siderophore–dependent growth assay. The assay was adapted from a previously published Fe(III)-Ybt–dependent growth assay,
and apo-Ybt was purified as previously described (16, 19). UTI89 was
grown overnight in LB broth at 37°C under shaking conditions and
then washed 3 times by centrifugation and resuspension in a volume of
PBS equal to the culture volume. The washed bacteria were inoculated
1:100 into YESCA or YESCA supplemented with 0.5 mM ethylenediamine-N,N′-bis(2-hydroxyphenylacetic acid) (EDDHA; Complete
Green Company). Prior to their addition, apo-Ybt and escherichelin
were preincubated for 2 hours with an equimolar amount of FeCl3 to
allow for complex formation. The Fe(III) complexes were added at
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a final concentration of 1 μM, and the cultures were grown at 37°C
under shaking conditions. Bacterial growth was monitored over time
by measuring the OD at 600 nm.
Escherichelin activity assay on P. aeruginosa. PW5011 (pvdA-E02::ISlacZ/hah) (55, 56) was grown in LB broth overnight at 37°C under shaking conditions and then back-diluted into succinate medium (25) at 108
CFU/ml. The growth experiments were performed in a final volume of
100 μl in 96-well plates. Escherichelin, solubilized in ethanol, was added to the cultures at increasing concentrations. The final ethanol (vehicle) concentration in all cultures was 5% (v/v). The cultures were grown
at 37°C under shaking conditions for 20 hours, at which point they were
serially diluted in PBS and plated on LB agar for CFU quantification.
Theoretical calculations. The theoretical calculations to identify
thermodynamically stable escherichelin-metal complexes were performed with the DFT method as previously described (15, 19). This
DFT approach was previously used to model a structure of Fe(III)Ybt that matched the published crystal structure (50). The simulated
Fe(III)-escherichelin complexes agree with a previously described
model of Fe(III)-escherichelin bound to FptA (25).
Escherichelin detection in urine. The clinical uncomplicated cystitis isolates were grown under iron-restricted conditions, and their
supernatants were analyzed for Ybt by LC-MRM. Seventeen of the
nineteen selected isolates were Ybt producers. The 2 Ybt nonproducers were used as controls. Two additional strains (Staphylococcus saprophyticus and Enterococcus sp.) were selected from the cohort to serve
as non–E. coli, Ybt-negative controls. After determining whether the
causative strain was a Ybt producer, the corresponding urine samples
were thawed on ice and then centrifuged at 15,996 g for 3 minutes to
remove any debris. To each 500 μl of urine, 12.5 μl 13C6-escherichelin IS and 3 μl 0.5 M FeCl3 were added. The samples were incubated
at room temperature for 15 minutes and then centrifuged at 15,996 g
for 5 minutes. The supernatant was then extracted on 96-well C18
solid-phase extraction plates with 80% methanol. Escherichelin was
detected by LC-MRM using the method described above. Escherichelin was detected in the bacterial interference trial specimens using the
same extraction and LC-MRM methods.
Statistics. GraphPad Prism 4 (GraphPad Software) was used to
perform statistical analysis and generate graphs for this study. All
P values were determined by unpaired, 2-tailed t test or 1-way ANOVA
with Dunnett’s multiple comparisons test. A P value of 0.05 or less was
considered statistically significant.
Study approval. The urine and bacterial specimens from patients
with uncomplicated cystitis were collected with the approval of the
Human Subjects Review Committee of the University of Washington.
All participants provided written informed consent for the sample collection and following analysis, prior to inclusion in the study. Study design,
inclusion and exclusion criteria, and sample preparation were previously
described (14, 86). β-Hemolytic E. coli isolates from urine cultures with
105 or more CFU/ml were selected from the cohort for analysis.
The HU2117 experimental human colonization study protocol
was approved by the FDA (investigational new drug [IND] 14007),
the IRB of Baylor College of Medicine, and the Houston VA Research
and Development committee and registered as a clinical trial (ClinicalTrials.gov identifier: NCT00554996. All participants provided
written informed consent prior to inclusion in the study. The study
design, inclusion and exclusion criteria, and specimen preparation
were previously reported (27).
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